Remarkable suppressive effect of consecutive low-dose cisplatin therapy on advanced ovarian clear cell adenocarcinoma

Oncol Rep. 1999 Sep-Oct;6(5):1035-7. doi: 10.3892/or.6.5.1035.

Abstract

Ovarian clear cell adenocarcinoma (OCCA) is known to be less responsive to cisplatin and most other anti-cancer drugs and to have a poorer prognosis than other ovarian cancers. We report a rare case of stage IIIc OCCA in a patient who has been treated postoperatively with cisplatin alone and continues to survive after 7.5 years. In this case, 25 mg/m2/day of cisplatin was administered for 5 consecutive days every 4 weeks. After remission, intermittent administration of cisplatin every 3 to 4 months was performed 8 times. This case suggests that induction and intermittent chemotherapy using consecutive low-dose cisplatin administration may be a useful treatment for OCCA.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma, Clear Cell / drug therapy*
  • Adenocarcinoma, Clear Cell / pathology
  • Adenocarcinoma, Clear Cell / physiopathology
  • Adenocarcinoma, Clear Cell / surgery
  • Antineoplastic Agents / administration & dosage*
  • Cisplatin / administration & dosage*
  • Female
  • Humans
  • Middle Aged
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / physiopathology
  • Ovarian Neoplasms / surgery
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Cisplatin